奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响

doi:10.3969/j.issn.1006-7795.2020.04.003

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (4): 514-519.doi: 10.3969/j.issn.1006-7795.2020.04.003

奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响

闵敏¹, 阮祥燕^1,2, 王虎生¹, 程姣姣¹, 罗穗豫¹, 许仲婷¹, 李萌¹, Alfred O. Mueck^1,2

1. 首都医科大学附属北京妇产医院内分泌科, 北京 100026;
2. 德国图宾根大学妇产医院妇女健康部与妇女健康研究中心, 图宾根D-72076, 德国

收稿日期:2020-05-08 出版日期:2020-08-21 发布日期:2020-07-22
通讯作者: 阮祥燕 E-mail:ruanxiangyan@163.com
基金资助:
北京市医院管理局"登峰"计划专项经费（DFL20181401），中国国际人才交流促进会医疗健康技术创新与人才培养专项基金（2017041900004，2018042000001）。

Effects of orlistat comprehensive intervention on metabolic syndrome and its components in overweight or obese polycystic ovarian syndrome patients

Min Min¹, Ruan Xiangyan^1,2, Wang Husheng¹, Cheng Jiaojiao¹, Luo Suiyu¹, Xu Zhongting¹, Li Meng¹, Alfred O. Mueck^1,2

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Department for Women's Health, University Women's Hospital and Research Center for Women's Health, University of Tubingen, Tubingen D-72076, Germany

Received:2020-05-08 Online:2020-08-21 Published:2020-07-22
Supported by:
This study was supported by Beijing Municipal Administration of Hospitals'Ascent Plan(DFL20181401),China International Talent Exchange Association Medical Health Technology Innovation and Talent Training Special Fund(2017041900004,2018042000001).

摘要/Abstract

摘要： 目的探讨奥利司他综合干预对合并代谢综合征（metabolic syndrome，MS）的超重或肥胖型多囊卵巢综合征（polycystic ovarian syndrome，PCOS）患者的MS组分及治疗有效率等的影响。方法选取2018年5月至2019年7月于首都医科大学附属北京妇产医院内分泌科就诊的62例合并MS的超重或肥胖型PCOS患者为研究对象，采用抽签法随机分为两组，单用屈螺酮炔雌醇片（Ⅱ）者作为对照组（n=18），奥利司他联合屈螺酮炔雌醇片（Ⅱ）者为观察组（n=44），观察不同方案治疗前后两组患者MS组分，体质量，性激素，肝、肾功能及MS治疗有效率等指标变化。结果治疗3个月后，两组的体质量、腰围、臀围、体质量指数（body mass index，BMI）、黄体生成素（luteinizing hormone，LH）、雌二醇（estradiol，E2）、总睾酮（total testosterone，TT）、游离睾酮（free testosterone，FT）、低密度脂蛋白胆固醇（low density lipoprotein-cholesterol，LDL-C）均明显下降，性激素结合球蛋白（sex hormone-binding globulin，SHBG）、高密度脂蛋白胆固醇（high density lipoprotein-cholesterol，HDL-C）明显升高。观察组体质量、BMI、LDL-C及空腹血糖（fasting plasma glucose，FPG）下降的程度大于对照组，差异有统计学意义（P<0.05）。治疗后两组MS治疗有效率比较，差异无统计学意义（P>0.05）。结论奥利司他联合屈螺酮炔雌醇片（Ⅱ）治疗在减轻体质量、改善脂代谢异常、降血糖等方面优于单用屈螺酮炔雌醇片（Ⅱ），为临床药物治疗方案的选择提供了依据。

关键词: 超重或肥胖, 多囊卵巢综合征, 代谢综合征, 奥利司他, 屈螺酮炔雌醇片(Ⅱ)

Abstract: Objective To investigate the effects of orlistat integrated intervention on metabolic syndrome (MS) components and therapeutic efficiency in overweight or obese polycystic ovarian syndrome (PCOS) patients with MS. Methods Totally 62 cases of overweight or obese PCOS patients with MS who visited the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University from May 2018 to July 2019 were selected and randomly divided into two groups,using drospirenone and ethinylestradiol tablets(Ⅱ) alone as the control group (n=18), orlistat plus drospirenone and ethinylestradiol tablets(Ⅱ) as the observation group (n=44).The changes of MS components, body mass, sex hormones, liver and kidney function and MS therapeutic efficiency were observed before and after different regimens. Results After 3 months of treatment, body weight, waist circumference, hip circumference, body mass index (BMI), luteinizing hormone(LH), estradiol(E2), total testosterone(TT), free testosterone (FT) and low density lipoprotein-cholesterol(LDL-C) of both two groups decreased significantly, while sex hormone-binding globulin(SHBG) and high density lipoprotein-cholesterol (HDL-C) increased significantly (P<0.05). Body weight, BMI, LDL-C and fasting plasma glucose (FPG) decreased more in the observation group than in control group (P<0.05). There was no significant difference in therapeutic efficiency of MS between the two groups after treatment. Conclusion Combinatorial treatment of orlistat with drospirenone and ethinylestradiol tablets(Ⅱ) is better than drospirenone and ethinylestradiol tablets(Ⅱ) alone in reducing body weight, improving abnormal lipid metabolism, lowering blood glucose and other aspects, which provides a basis for the selection of clinical drug treatment plan.

Key words: overweight or obese, polycystic ovary syndrome, metabolic syndrome, orlistat, drospirenone and ethinylestradioltablets(Ⅱ)

中图分类号:

R711

闵敏, 阮祥燕, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响[J]. 首都医科大学学报, 2020, 41(4): 514-519.

Min Min, Ruan Xiangyan, Wang Husheng, Cheng Jiaojiao, Luo Suiyu, Xu Zhongting, Li Meng, Alfred O. Mueck. Effects of orlistat comprehensive intervention on metabolic syndrome and its components in overweight or obese polycystic ovarian syndrome patients[J]. Journal of Capital Medical University, 2020, 41(4): 514-519.

参考文献 18

[1]	Trikudanathan S. Polycystic ovarian syndrome[J]. Med Clin North Am, 2015,99(1):221-235.
[2]	Peigné M, Dewailly D. Long term complications of polycystic ovary syndrome (PCOS)[J]. Ann Endocrinol (Paris), 2014,75(4):194-199.
[3]	Schnack L L, Romani A M P. The metabolic syndrome and the relevance of nutrients for its onset[J]. Recent Pat Biotechnol, 2017,11(2):101-119.
[4]	Ali A T. Polycystic ovary syndrome and metabolic syndrome[J]. Ceska Gynekol, 2015,80(4):279-289.
[5]	Sherling D H, Perumareddi P, Hennekens C H. Metabolic syndrome[J]. J Cardiovasc Pharmacol Ther, 2017,22(4):365-367.
[6]	Ruan X, Li M, Mueck A O. Why does polycystic ovary syndrome (PCOS) need long-term management?[J]. Curr Pharmaceut Design, 2018, 24(39):4685-4692.
[7]	Li Y, Chen C, Ma Y, et al. Multi-system reproductive metabolic disorder:significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS)[J]. Life Sci, 2019,228:167-175.
[8]	中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合症中国诊疗指南[J]. 中华妇产科杂志, 2018,53(1):2-6.
[9]	Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J]. Hum Reprod,2004,19(1):41-47.
[10]	中国肥胖问题工作组. 中国成人超重和肥胖症预防与控制指南[J]. 营养学报, 2004,26(1):1-4.
[11]	Alberti K G, Zimmet P, Shaw J, et al. The metabolic syndrome-a new worldwide definition[J]. Lancet,2005,366(9491):1059-1062.
[12]	张春梅,赵越,乔杰.多囊卵巢综合征合并代谢综合征临床特点及治疗进展[J].中国实用妇科与产科杂志,2016,32(9):915-918.
[13]	Panda S R, Jain M, Jain S, et al. Effect of orlistat versus metformin in various aspects of polycystic ovarian syndrome:a systematic review of randomized control trials[J]. J Obstetr Gynaecol India, 2018, 68(5):336-343.
[14]	Patni N, Quittner C, Garg A. Orlistat therapy for children with type 1 hyperlipoproteinemia:a randomized clinical trial[J]. J Clin Endocrinol Metab, 2018, 103(6):2403-2407.
[15]	Saleh A, ElFayoumi H M,Youns M, et al. Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions[J]. Naunyn-Schmiedeberg's Arch Pharmacol, 2019,392(2):165-175.
[16]	Keevil B G, Adaway J. Assessment of free testosterone concentration[J]. J Steroid Biochem Mol Biol, 2019, 190:207-211.
[17]	McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome[J]. Clin Dermatol, 2018,36(1):14-20.
[18]	李宾,姜晓峰.代谢综合征的研究进展[J].国际检验医学杂志,2018,39(24):2996-3001.

奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响

Effects of orlistat comprehensive intervention on metabolic syndrome and its components in overweight or obese polycystic ovarian syndrome patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 18

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏志燕, 刘薇, 史婷婷. 老年2型糖尿病患者血尿酸浓度与代谢综合征的相关性分析[J]. 首都医科大学学报, 2023, 44(1): 137-142.
[2]	李健, 白文佩, 江波, 白栎然, 吴凤云. 生酮饮食对超重/肥胖多囊卵巢综合征女性月经及生育力的影响[J]. 首都医科大学学报, 2021, 42(6): 1021-1025.
[3]	王虎生, 阮祥燕, 程姣姣, Alfred O. Mueck. 肥胖型多囊卵巢综合征的氧化应激与脂代谢关系的研究[J]. 首都医科大学学报, 2021, 42(4): 540-546.
[4]	杨瑜, 阮祥燕, 鞠蕊, 许新, 谷牧青, 程姣姣. 屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响[J]. 首都医科大学学报, 2021, 42(4): 547-552.
[5]	刘真, 殷冬梅, 战思恩, 阮祥燕. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4): 588-595.
[6]	来璇, 张爱华. 代谢综合征对慢性肾脏病患者生存预后的影响[J]. 首都医科大学学报, 2021, 42(4): 609-614.
[7]	王景尚, 尹晓丹, 何军琴, 武颖, 张莹, 李宪锐. 来曲唑联合高糖高脂饮食构建多囊卵巢综合征伴胰岛素抵抗大鼠模型研究[J]. 首都医科大学学报, 2021, 42(3): 436-442.
[8]	张黎锐, 郑薇, 刘程, 梁馨, 张莉, 田志红, 李光辉. 多囊卵巢综合征孕妇妊娠期增重模式与母儿结局的关系[J]. 首都医科大学学报, 2021, 42(2): 169-176.
[9]	王宾红, 阮祥燕, 鞠蕊, 豆竹丽, 秦爽, 张露平, 许新, 杨瑜, Alfred O. Mueck. 综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响[J]. 首都医科大学学报, 2020, 41(4): 520-524.
[10]	豆竹丽, 阮祥燕, 鞠蕊, 王宾红, 秦爽, 许新, 杨瑜, 张露平. 综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果[J]. 首都医科大学学报, 2020, 41(4): 525-529.
[11]	秦爽, 阮祥燕, 王宾红, 鞠蕊, 张露平, 豆竹丽, 程姣姣, 金婧. 多囊卵巢综合征患者促排卵周期中成熟卵泡性激素浓度对妊娠的影响[J]. 首都医科大学学报, 2020, 41(4): 530-535.
[12]	王延雪, 胡虹英, 李新刚, 鹿星梦, 郜桂菊, 梁洪远, 肖江, 杨涤, 王芳, 韩晓涛. 初治人类免疫缺陷病毒感染者合并代谢综合征及心血管病风险状况及其临床特点分析[J]. 首都医科大学学报, 2020, 41(1): 40-44.
[13]	修双玲, 穆志静, 孙丽娜, 赵蕾, 韩青, 曹雪霞. 老年2型糖尿病代谢综合征患者骨质疏松危险因素研究[J]. 首都医科大学学报, 2020, 41(1): 108-112.
[14]	庄文旭, 张伟波, 朱有为, 朱益, 蔡军. 对精神分裂症躯体健康问题的生活方式干预[J]. 首都医科大学学报, 2019, 40(5): 698-702.
[15]	阮祥燕, 张露平, 代荫梅, 王虎生, 金凤羽, 谷牧青, 程姣姣, 鞠蕊, 闵敏, Thomas Roemer. 门诊微型宫腔镜检查在不孕症患者中的临床应用[J]. 首都医科大学学报, 2019, 40(4): 549-553.